United States Patent 6,071,537: Scope, Claim Boundaries, and US Patent Landscape for Obesity Treatment

US Patent 6,071,537 claims a method of treating obesity by administering a compound defined by formula I (and dependent claims narrow to specific embodiments and dose ranges). The patent’s practical scope is defined by (1) the structural variables in formula I, (2) the topiramate embodiment, and (3) administration dose bands.

What does US 6,071,537 claim, at the highest level?

Claim set overview

The independent claim is a therapeutic-use method claim:

Claim 1:
A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound of formula I, where:
- X is CH2 or oxygen
- R1 is hydrogen or alkyl
- R2, R3, R4, R5 are each independently hydrogen or lower alkyl
- If X is oxygen, then R2 and R3 and/or R4 and R5 together may form a methylenedioxy group per formula II, where:
- R6 and R7 are hydrogen, lower alkyl, or form the ring when alkyl is present
- R6 and R7 are joined to form a cyclopentyl or cyclohexyl ring

Claims 2-4 narrow claim 1 by specifying the compound and dose.

Claim 2: Formula I compound is topiramate
Claim 3: Dose is about 50 to 400 mg
Claim 4: Dose is about 25 to 200 mg

Legal characterization

This is a method-of-use patent for an already-established pharmacophore class. Scope is therefore determined by whether a competitor’s obesity therapy involves: 1) the claimed therapeutically effective administration,
2) to a mammal with obesity, and
3) uses a compound that fits formula I (or the explicit topiramate embodiment).

Product formulation, route, and regimen details are not stated in the excerpted claims, so infringement analysis typically turns on whether the administered compound and dose fall within the claimed boundaries.

How broad is Claim 1’s structural coverage (formula I)?

Claim 1’s breadth comes from variable substitution allowances:

Core scaffold feature controlled by X:
- X can be CH2 or oxygen, meaning the scaffold permits either a methylene or an oxygen linkage at the corresponding position in the structure.
Substitution patterns controlled by R-group set:
- R1: hydrogen or alkyl
- R2-R5: hydrogen or lower alkyl, independently

This design gives a large chemical genus rather than a single analog.

Methylenedioxy option when X is oxygen

If X is oxygen, the claim permits additional structural complexity through a methylenedioxy substitution scheme:

R2 and R3 and/or R4 and R5 together may be a methylenedioxy group per formula II.
In formula II, R6 and R7 can be:
- hydrogen or lower alkyl (independent)
- OR alkyl units joined to form a cyclopentyl or cyclohexyl ring.

This expands scope beyond “simple” methylenedioxy patterns by allowing ring-fused / ring-joined variants through the R6/R7 linkage rule.

Practical implication for landscape work

In portfolio mapping, Claim 1 behaves like a genus method claim: any obesity therapy using a compound that matches the claimed formula I variables can fall within scope even if it is not named. The dependent “topiramate” claim further increases enforcement leverage against therapies using that specific compound.

Where does the patent narrow, and what does that do to enforceability?

Claim 2: Topiramate is an explicit covered embodiment

Claim 2 states that the formula I compound is topiramate.

That removes interpretive ambiguity for one substance and gives a clean enforcement pathway for products or regimens where:

topiramate is administered,
for obesity treatment,
at a therapeutically effective amount.

Claims 3 and 4: Dose bands

Claim 3: about 50 to 400 mg
Claim 4: about 25 to 200 mg

These overlapping ranges create two covered dose windows. In an infringement posture, dose is usually fact-dependent:

if a regimen fits one of the bands, the dose limitation is satisfied;
if a regimen is outside, it may still be argued as “therapeutically effective” under claim 1 but would not meet the specific dependent claims 3 and 4.

Claim dependency structure

Claims 3 and 4 depend from claim 1, so they also inherit the formula I structure limitations and obesity-use limitation.
Claim 2 depends from claim 1, so it inherits all formula I conditions, but narrows the compound to topiramate.

What is the enforceable “core” scope in the US?

Core protected concept

The patent protects a specific therapeutic use: administering a compound of formula I (including topiramate) for treating obesity in a mammal.

Core infringement triggers (operational)

A party is exposed where its obesity program or clinical use includes:

administration of a compound that meets formula I variable definitions, and
use in obesity treatment, and
dosing that falls within the dependent claim ranges if targeting claims 3/4.

Key boundary conditions implied by the claim text

Therapeutically effective amount is not defined by route or frequency in the excerpt; it is therefore broadly captured as “enough to treat obesity.”
Mammal covers humans and veterinary obesity models.
The excerpted claims do not restrict to specific pharmaceutical forms, so infringement can attach to tablets, capsules, sprinkles, extended-release, or other dosage forms if the active ingredient and dosing meet the claim.

How does this patent likely sit in the US obesity and CNS drug landscape?

Two-layer enforcement posture

This patent supports a two-track approach:

1) Direct topiramate posture
Claim 2 plus the method-of-use framing creates a clear hook against obesity treatment regimens using topiramate.

2) Genus-based posture
Claim 1 provides coverage for additional analogs meeting formula I constraints, even if not named.

Competitive mapping implication

Companies developing obesity therapies using topiramate (alone or as part of combination regimens) should assess:

whether the topiramate dose is within the claimed windows (for claims 3/4),
whether the use is explicitly for obesity treatment (versus off-label or other indications),
and whether analogs used as actives fit formula I variables.

What does Claim 1’s formula structure imply for freedom-to-operate (FTO) screening?

Because formula I allows:

X being CH2 or oxygen,
R1 being hydrogen or alkyl,
R2-R5 being hydrogen or lower alkyl,
plus an optional methylenedioxy scheme when X is oxygen with cyclopentyl/cyclohexyl ring formation conditions,

FTO screening must treat the claim as a chemistry filter followed by a use-and-dose filter.

Screening logic for competitors (high signal)

1) Active ingredient match

If the therapy uses topiramate, the analysis is direct under claim 2.
If it uses a related scaffold, map the structure to formula I variables.

2) Use in obesity

Evidence and label indications that tie administration to obesity treatment strengthen infringement exposure for method claims.

3) Dose window hit

If topiramate dose is within 25-200 mg or 50-400 mg, claim 3/4 exposures are heightened.

What parts of the claim text create the biggest legal friction in interpretation?

“Formula I” variable definitions

The claim uses variable-based structural language. In practice, the high-friction elements are:

X positional meaning (CH2 vs oxygen),
how “lower alkyl” is construed versus broader alkyl,
how the methylenedioxy pattern is applied when “R2 and R3 and/or R4 and R5 together may be” the group,
and how the ring formation condition (R6 and R7 joined to form cyclopentyl or cyclohexyl) is satisfied.

“Therapeutically effective amount” coupled with obesity

This is common in method-of-use patents and typically turns on:

whether a regimen is designed and administered with obesity treatment intent,
and whether clinical outcomes support “effective amount” in the obesity context.

Landscape implications: what this patent is likely protecting in practice

Given the explicit topiramate embodiment and the obesity method framing, US 6,071,537 most directly supports protection against:

obesity treatment programs involving topiramate,
and obesity treatment programs using closely related analogs that fall into formula I substitution patterns.

Where the landscape becomes strategic is in the interaction of:

the claimed genus, and
ongoing innovation around CNS-active small molecules tested for weight loss indications.

Key Takeaways

US 6,071,537 is a method-of-use patent for obesity treatment in mammals via administration of formula I compounds.
Claim 1 covers a broad genus defined by X (CH2/oxygen), R1 (H/alkyl), and R2-R5 (H/lower alkyl), plus a methylenedioxy/more complex ring condition when X is oxygen.
Claim 2 explicitly narrows to topiramate, creating a clean enforcement path for obesity treatment regimens using topiramate.
Claims 3 and 4 add dose constraints: 50-400 mg and 25-200 mg bands, respectively, with dependent claim dependence on claim 1.
For landscape and FTO, exposure is driven by active ingredient structural match (formula I) plus obesity-use intent and, for dependent claims, dose window alignment.

FAQs

1) Does US 6,071,537 protect topiramate itself or only obesity treatment?

It protects the method of treating obesity by administering a compound of formula I, with claim 2 explicitly covering topiramate for that obesity use. The excerpted claims are not product claims.

2) What structural elements must a compound have to fall under Claim 1?

It must match formula I variable conditions: X is CH2 or oxygen; R1 is hydrogen or alkyl; R2-R5 are hydrogen or lower alkyl, with additional methylenedioxy/ring-joined possibilities when X is oxygen.

3) What dose ranges are explicitly covered?

Dependent claims specify:

about 50 to 400 mg (Claim 3)
about 25 to 200 mg (Claim 4)

4) If a regimen is effective but outside the dependent dose windows, is it outside the patent?

Not necessarily. Claims 3 and 4 are dependent and add specific dose limitations, but claim 1 still covers “therapeutically effective amount” for obesity if the compound fits formula I.

5) How should portfolio teams screen competitors for infringement exposure?

Screen for three elements in order: (1) active compound structure versus formula I, (2) obesity treatment use, and (3) dose alignment with 25-200 mg or 50-400 mg for the dependent claims.

References

[1] US Patent 6,071,537. “Method for treating obesity using compounds of formula I.” United States Patent and Trademark Office.

Title:	Anticonvulsant derivatives useful in treating obesity
Abstract:	A method for treating obesity comprising administering a therapeutically effective amount of a compound of the formula: ##STR1## is disclosed.
Inventor(s):	Richard P. Shank
Assignee:	Vivus LLC , Ortho Pharmaceutical Corp
Application Number:	US08/881,009
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,071,537
Patent Claim Types: see list of patent claims	Use;
Patent landscape, scope, and claims:	United States Patent 6,071,537: Scope, Claim Boundaries, and US Patent Landscape for Obesity Treatment US Patent 6,071,537 claims a method of treating obesity by administering a compound defined by formula I (and dependent claims narrow to specific embodiments and dose ranges). The patent’s practical scope is defined by (1) the structural variables in formula I, (2) the topiramate embodiment, and (3) administration dose bands. What does US 6,071,537 claim, at the highest level? Claim set overview The independent claim is a therapeutic-use method claim: Claim 1: A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound of formula I, where: X is CH2 or oxygen R1 is hydrogen or alkyl R2, R3, R4, R5 are each independently hydrogen or lower alkyl If X is oxygen, then R2 and R3 and/or R4 and R5 together may form a methylenedioxy group per formula II, where: R6 and R7 are hydrogen, lower alkyl, or form the ring when alkyl is present R6 and R7 are joined to form a cyclopentyl or cyclohexyl ring Claims 2-4 narrow claim 1 by specifying the compound and dose. Claim 2: Formula I compound is topiramate Claim 3: Dose is about 50 to 400 mg Claim 4: Dose is about 25 to 200 mg Legal characterization This is a method-of-use patent for an already-established pharmacophore class. Scope is therefore determined by whether a competitor’s obesity therapy involves: 1) the claimed therapeutically effective administration, 2) to a mammal with obesity, and 3) uses a compound that fits formula I (or the explicit topiramate embodiment). Product formulation, route, and regimen details are not stated in the excerpted claims, so infringement analysis typically turns on whether the administered compound and dose fall within the claimed boundaries. How broad is Claim 1’s structural coverage (formula I)? Claim 1’s breadth comes from variable substitution allowances: Core scaffold feature controlled by X: X can be CH2 or oxygen, meaning the scaffold permits either a methylene or an oxygen linkage at the corresponding position in the structure. Substitution patterns controlled by R-group set: R1: hydrogen or alkyl R2-R5: hydrogen or lower alkyl, independently This design gives a large chemical genus rather than a single analog. Methylenedioxy option when X is oxygen If X is oxygen, the claim permits additional structural complexity through a methylenedioxy substitution scheme: R2 and R3 and/or R4 and R5 together may be a methylenedioxy group per formula II. In formula II, R6 and R7 can be: hydrogen or lower alkyl (independent) OR alkyl units joined to form a cyclopentyl or cyclohexyl ring. This expands scope beyond “simple” methylenedioxy patterns by allowing ring-fused / ring-joined variants through the R6/R7 linkage rule. Practical implication for landscape work In portfolio mapping, Claim 1 behaves like a genus method claim: any obesity therapy using a compound that matches the claimed formula I variables can fall within scope even if it is not named. The dependent “topiramate” claim further increases enforcement leverage against therapies using that specific compound. Where does the patent narrow, and what does that do to enforceability? Claim 2: Topiramate is an explicit covered embodiment Claim 2 states that the formula I compound is topiramate. That removes interpretive ambiguity for one substance and gives a clean enforcement pathway for products or regimens where: topiramate is administered, for obesity treatment, at a therapeutically effective amount. Claims 3 and 4: Dose bands Claim 3: about 50 to 400 mg Claim 4: about 25 to 200 mg These overlapping ranges create two covered dose windows. In an infringement posture, dose is usually fact-dependent: if a regimen fits one of the bands, the dose limitation is satisfied; if a regimen is outside, it may still be argued as “therapeutically effective” under claim 1 but would not meet the specific dependent claims 3 and 4. Claim dependency structure Claims 3 and 4 depend from claim 1, so they also inherit the formula I structure limitations and obesity-use limitation. Claim 2 depends from claim 1, so it inherits all formula I conditions, but narrows the compound to topiramate. What is the enforceable “core” scope in the US? Core protected concept The patent protects a specific therapeutic use: administering a compound of formula I (including topiramate) for treating obesity in a mammal. Core infringement triggers (operational) A party is exposed where its obesity program or clinical use includes: administration of a compound that meets formula I variable definitions, and use in obesity treatment, and dosing that falls within the dependent claim ranges if targeting claims 3/4. Key boundary conditions implied by the claim text Therapeutically effective amount is not defined by route or frequency in the excerpt; it is therefore broadly captured as “enough to treat obesity.” Mammal covers humans and veterinary obesity models. The excerpted claims do not restrict to specific pharmaceutical forms, so infringement can attach to tablets, capsules, sprinkles, extended-release, or other dosage forms if the active ingredient and dosing meet the claim. How does this patent likely sit in the US obesity and CNS drug landscape? Two-layer enforcement posture This patent supports a two-track approach: 1) Direct topiramate posture Claim 2 plus the method-of-use framing creates a clear hook against obesity treatment regimens using topiramate. 2) Genus-based posture Claim 1 provides coverage for additional analogs meeting formula I constraints, even if not named. Competitive mapping implication Companies developing obesity therapies using topiramate (alone or as part of combination regimens) should assess: whether the topiramate dose is within the claimed windows (for claims 3/4), whether the use is explicitly for obesity treatment (versus off-label or other indications), and whether analogs used as actives fit formula I variables. What does Claim 1’s formula structure imply for freedom-to-operate (FTO) screening? Because formula I allows: X being CH2 or oxygen, R1 being hydrogen or alkyl, R2-R5 being hydrogen or lower alkyl, plus an optional methylenedioxy scheme when X is oxygen with cyclopentyl/cyclohexyl ring formation conditions, FTO screening must treat the claim as a chemistry filter followed by a use-and-dose filter. Screening logic for competitors (high signal) 1) Active ingredient match If the therapy uses topiramate, the analysis is direct under claim 2. If it uses a related scaffold, map the structure to formula I variables. 2) Use in obesity Evidence and label indications that tie administration to obesity treatment strengthen infringement exposure for method claims. 3) Dose window hit If topiramate dose is within 25-200 mg or 50-400 mg, claim 3/4 exposures are heightened. What parts of the claim text create the biggest legal friction in interpretation? “Formula I” variable definitions The claim uses variable-based structural language. In practice, the high-friction elements are: X positional meaning (CH2 vs oxygen), how “lower alkyl” is construed versus broader alkyl, how the methylenedioxy pattern is applied when “R2 and R3 and/or R4 and R5 together may be” the group, and how the ring formation condition (R6 and R7 joined to form cyclopentyl or cyclohexyl) is satisfied. “Therapeutically effective amount” coupled with obesity This is common in method-of-use patents and typically turns on: whether a regimen is designed and administered with obesity treatment intent, and whether clinical outcomes support “effective amount” in the obesity context. Landscape implications: what this patent is likely protecting in practice Given the explicit topiramate embodiment and the obesity method framing, US 6,071,537 most directly supports protection against: obesity treatment programs involving topiramate, and obesity treatment programs using closely related analogs that fall into formula I substitution patterns. Where the landscape becomes strategic is in the interaction of: the claimed genus, and ongoing innovation around CNS-active small molecules tested for weight loss indications. Key Takeaways US 6,071,537 is a method-of-use patent for obesity treatment in mammals via administration of formula I compounds. Claim 1 covers a broad genus defined by X (CH2/oxygen), R1 (H/alkyl), and R2-R5 (H/lower alkyl), plus a methylenedioxy/more complex ring condition when X is oxygen. Claim 2 explicitly narrows to topiramate, creating a clean enforcement path for obesity treatment regimens using topiramate. Claims 3 and 4 add dose constraints: 50-400 mg and 25-200 mg bands, respectively, with dependent claim dependence on claim 1. For landscape and FTO, exposure is driven by active ingredient structural match (formula I) plus obesity-use intent and, for dependent claims, dose window alignment. FAQs 1) Does US 6,071,537 protect topiramate itself or only obesity treatment? It protects the method of treating obesity by administering a compound of formula I, with claim 2 explicitly covering topiramate for that obesity use. The excerpted claims are not product claims. 2) What structural elements must a compound have to fall under Claim 1? It must match formula I variable conditions: X is CH2 or oxygen; R1 is hydrogen or alkyl; R2-R5 are hydrogen or lower alkyl, with additional methylenedioxy/ring-joined possibilities when X is oxygen. 3) What dose ranges are explicitly covered? Dependent claims specify: about 50 to 400 mg (Claim 3) about 25 to 200 mg (Claim 4) 4) If a regimen is effective but outside the dependent dose windows, is it outside the patent? Not necessarily. Claims 3 and 4 are dependent and add specific dose limitations, but claim 1 still covers “therapeutically effective amount” for obesity if the compound fits formula I. 5) How should portfolio teams screen competitors for infringement exposure? Screen for three elements in order: (1) active compound structure versus formula I, (2) obesity treatment use, and (3) dose alignment with 25-200 mg or 50-400 mg for the dependent claims. References [1] US Patent 6,071,537. “Method for treating obesity using compounds of formula I.” United States Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1285	⤷ Start Trial
African Regional IP Organization (ARIPO)	9801429	⤷ Start Trial
Austria	224189	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,071,537

Summary for Patent: 6,071,537